Opus Genetics to Present OPGx-BEST1 Phase 1/2 Data
RESEARCH TRIANGLE PARK, N.C., September 2, 2026 Opus Genetics, Inc. plans to present topline clinical data from Cohort 1...
celiac disease
Advertisement
Teva Reports Positive Phase 2a Results for TEV ‘408 in Celiac Disease
TEL AVIV, Israel, September 2, 2026 Teva Pharmaceutical Industries Ltd. has reported positive topline results from its ongoing Phase...
argenx Completes Forte Biosciences Acquisition for FB102
Amsterdam, the Netherlands – August 27, 2026 argenx announced the successful completion of its acquisition of Forte Biosciences, Inc.,...
argenx SE Expands Immunology Pipeline with Forte Biosciences Deal
Amsterdam, the Netherlands and Dallas, Texas – July 27, 2026 argenx has entered into a definitive agreement to acquire...
FDA Moves to Improve Gluten Ingredient Disclosure in Foods
Washington, D.C. | January 21, 2026 — The U.S. Food and Drug Administration (FDA) has taken a significant step...
Advertisement
